ANVS | Annovis Bio, Inc. | [NYSE]
Index- P/E- EPS (ttm)-3.57 Insider Own30.74% Shs Outstand8.20M Perf Week-2.24%
Market Cap111.68M Forward P/E- EPS next Y-3.50 Insider Trans0.00% Shs Float5.31M Perf Month-11.78%
Income-29.20M PEG- EPS next Q-1.14 Inst Own9.10% Short Float / Ratio7.41% / 4.60 Perf Quarter-22.85%
Sales- P/S- EPS this Y-63.40% Inst Trans-3.85% Short Interest0.39M Perf Half Y1.16%
Book/sh2.46 P/B5.17 EPS next Y23.70% ROA-89.40% Target Price46.00 Perf Year29.32%
Cash/sh1.91 P/C6.65 EPS next 5Y- ROE-102.70% 52W Range8.98 - 23.91 Perf YTD-2.46%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.21% Beta1.22
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low45.88% ATR0.94
Employees5 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)42.86 Volatility7.44% 6.51%
OptionableNo Debt/Eq0.00 EPS Q/Q-85.20% Profit Margin- Rel Volume0.16 Prev Close12.72
ShortableYes LT Debt/Eq0.00 EarningsApr 03 BMO Payout- Avg Volume85.60K Price13.10
Recom1.70 SMA20-6.16% SMA50-12.23% SMA200-7.58% Volume7,849 Change2.99%
Date Action Analyst Rating Change Price Target Change
Jul-07-21Reiterated Maxim Group Buy $45 → $150
May-11-23 07:00AM
May-04-23 09:55AM
Apr-27-23 07:00AM
Apr-25-23 11:36AM
Apr-21-23 10:00AM
07:10AM Loading…
Apr-20-23 07:00AM
Apr-19-23 07:30AM
Apr-18-23 10:00AM
Apr-13-23 07:30AM
Apr-11-23 09:04AM
Apr-07-23 12:00PM
Apr-06-23 06:36AM
07:30AM Loading…
Apr-03-23 07:30AM
Mar-31-23 11:44AM
Mar-30-23 08:50AM
Mar-29-23 12:27PM
Mar-28-23 10:41AM
Mar-27-23 12:09PM
Mar-22-23 07:30AM
Mar-21-23 11:24AM
Mar-15-23 11:52AM
Mar-14-23 09:06AM
Mar-13-23 10:19AM
Mar-08-23 09:40AM
09:59AM Loading…
Feb-17-23 09:59AM
Feb-10-23 01:36PM
Feb-08-23 07:30AM
Feb-01-23 09:55AM
Jan-25-23 07:30AM
Jan-06-23 07:30AM
Dec-26-22 09:38AM
Dec-02-22 09:55AM
Nov-16-22 09:55AM
Nov-08-22 05:35PM
Oct-26-22 06:38AM
Oct-20-22 07:30AM
Oct-11-22 07:30AM
Oct-07-22 12:57PM
Oct-06-22 09:24PM
Sep-29-22 07:30AM
Sep-13-22 07:30AM
Sep-10-22 09:55AM
Sep-08-22 07:30AM
Aug-29-22 04:00PM
Aug-26-22 10:07AM
Aug-25-22 01:12PM
Aug-24-22 07:30AM
Aug-08-22 07:30AM
Aug-01-22 07:30AM
Jul-14-22 07:30AM
Jul-07-22 10:17AM
Jun-28-22 06:30AM
Jun-09-22 08:30AM
May-05-22 08:55AM
May-04-22 08:30AM
Apr-28-22 04:30PM
Apr-26-22 07:15AM
Apr-11-22 08:30AM
Mar-23-22 08:30AM
Mar-21-22 01:16PM
Mar-18-22 08:30AM
Mar-08-22 08:30AM
Mar-03-22 08:30AM
Jan-28-22 02:01PM
Jan-25-22 12:14PM
Jan-19-22 04:42AM
Jan-10-22 08:30AM
Jan-07-22 12:29PM
Jan-05-22 08:30AM
Jan-03-22 08:30AM
Dec-20-21 08:30AM
Dec-14-21 08:29AM
Nov-20-21 06:23AM
Nov-15-21 09:00AM
Nov-12-21 10:26AM
Nov-09-21 08:30AM
Nov-03-21 10:43AM
Nov-02-21 08:30AM
Oct-18-21 08:10AM
Oct-15-21 09:00PM
Oct-14-21 07:10PM
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maccecchini Maria-LuisaPresident and CEOFeb 06Option Exercise0.1452,7557,3861,040,489Feb 08 05:11 PM